Meissner WG - Search Results

1

Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?

Bassil F, Fernagut PO, Bezard E, Meissner WG. Bassil F, et al. Among authors: meissner wg. Prog Neurobiol. 2014 Jul;118:1-18. doi: 10.1016/j.pneurobio.2014.02.005. Epub 2014 Feb 28. Prog Neurobiol. 2014. PMID: 24582776 Review.

2

Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E. Meissner W, et al. Mol Neurobiol. 2003 Dec;28(3):209-18. doi: 10.1385/MN:28:3:209. Mol Neurobiol. 2003. PMID: 14709785 Review.

3

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Meissner W, et al. Trends Pharmacol Sci. 2004 May;25(5):249-53. doi: 10.1016/j.tips.2004.03.003. Trends Pharmacol Sci. 2004. PMID: 15120490 Review.

4

High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster.

Reese R, Charron G, Nadjar A, Aubert I, Thiolat ML, Hamann M, Richter A, Bezard E, Meissner WG. Reese R, et al. Among authors: meissner wg. Neurobiol Dis. 2009 Sep;35(3):399-405. doi: 10.1016/j.nbd.2009.05.022. Epub 2009 Jun 6. Neurobiol Dis. 2009. PMID: 19501651

5

Deep brain stimulation changes basal ganglia output nuclei firing pattern in the dystonic hamster.

Leblois A, Reese R, Labarre D, Hamann M, Richter A, Boraud T, Meissner WG. Leblois A, et al. Among authors: meissner wg. Neurobiol Dis. 2010 May;38(2):288-98. doi: 10.1016/j.nbd.2010.01.020. Epub 2010 Feb 4. Neurobiol Dis. 2010. PMID: 20138992

6

Priorities in Parkinson's disease research.

Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E. Meissner WG, et al. Nat Rev Drug Discov. 2011 May;10(5):377-93. doi: 10.1038/nrd3430. Nat Rev Drug Discov. 2011. PMID: 21532567 Review.

7

Methods for treating neurological conditions (WO2011159945).

Meissner WG. Meissner WG. Expert Opin Ther Pat. 2012 Jul;22(7):847-52. doi: 10.1517/13543776.2012.699524. Epub 2012 Jun 15. Expert Opin Ther Pat. 2012. PMID: 22697132

8

Movement disorders in 2013: diagnosing and treating PD-the earlier the better?

Tison F, Meissner WG. Tison F, et al. Among authors: meissner wg. Nat Rev Neurol. 2014 Feb;10(2):65-6. doi: 10.1038/nrneurol.2013.273. Epub 2014 Jan 7. Nat Rev Neurol. 2014. PMID: 24394288 Review. No abstract available.

9

Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy.

Flabeau O, Meissner WG, Ozier A, Berger P, Tison F, Fernagut PO. Flabeau O, et al. Among authors: meissner wg. Mov Disord. 2014 Mar;29(3):388-95. doi: 10.1002/mds.25804. Epub 2014 Jan 17. Mov Disord. 2014. PMID: 24442757

10

Demyelination in a patient receiving ustekinumab for refractory Crohn's disease.

Badat Y, Meissner WG, Laharie D. Badat Y, et al. Among authors: meissner wg. J Crohns Colitis. 2014 Sep;8(9):1138-9. doi: 10.1016/j.crohns.2014.02.004. Epub 2014 Feb 23. J Crohns Colitis. 2014. PMID: 24572561 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results